OVA Peptide (323-339)

<strong>OVA Peptide (323-339) </strong>_x000D_ <strong>Catalog number:</strong> B2013054_x000D_ <strong>Lot number:</strong> Batch Dependent_x000D_ <strong>Expiration Date:</strong> Batch dependent_x000D_ <strong>Amount:</strong> 500 ug_x000D_ <strong>Molecular Weight or Concentration:</strong> N/A_x000D_ <strong>Supplied as:</strong> Lyophilized Powder_x000D_ <strong>Applications:</strong> molecular tool for various biochemical applications_x000D_ <strong>Storage:</strong> -20°C_x000D_ <strong>Keywords:</strong> Ovalbumin, Egg albumin, SERPINB14_x000D_ <strong>Grade:</strong> Biotechnology grade. All products are highly pure. All solutions are made with Type I ultrapure water (resistivity &gt;18 MΩ-cm) and are filtered through 0.22 um._x000D_ _x000D_ <strong>References:</strong>_x000D_ 1: Sun LZ, Elsayed S, Aasen TB, Van Do T, Aardal NP, Florvaag E, Vaali K. Comparison between ovalbumin and ovalbumin peptide 323-339 responses in allergic mice: humoral and cellular aspects Scand J Immunol. 2010 May;71(5):329-35._x000D_ 2: McFarland BJ, Sant AJ, Lybrand TP, Beeson C. Ovalbumin(323-339) peptide binds to the major histocompatibility complex class II I-A(d) protein using two functionally distinct registers Biochemistry. 1999 Dec 14;38(50):16663-70._x000D_ 3: Xiao M, Xie L, Cao G, Lei S, Wang P, Wei Z, Luo Y, Fang J, Yang X, Huang Q, Xu L, Guo J, Wen S, Wang Z, Wu Q, Tang J, Wang L, Chen X, Chen C, Zhang Y, Yao W, Ye J, He R, Huang J, Ye L. CD4(+) T-cell epitope-based heterologous prime-boost vaccination potentiates anti-tumor immunity and PD-1/PD-L1 immunotherapy J Immunother Cancer. 2022 May;10(5):e004022._x000D_ 4: Renz H, Bradley K, Larsen GL, McCall C, Gelfand EW. Comparison of the allergenicity of ovalbumin and ovalbumin peptide 323-339. Differential expansion of V beta-expressing T cell populations J Immunol. 1993 Dec 15;151(12):7206-13._x000D_ 5: Moss DL, Mettu RR, Landry SJ. The Serpin-like Loop Insertion of Ovalbumin Increases the Stability and Decreases the OVA 323-339 Epitope Processing Efficiency Biochemistry. 2021 May 25;60(20):1578-1586._x000D_ 6: Fukushima A, Nishino K, Yoshida O, Ueno H. Characterization of the immunopathogenic responses to ovalbumin peptide 323-339 in experimental immune-mediated blepharoconjunctivitis in Lewis rats Curr Eye Res. 1998 Aug;17(8):763-9._x000D_ 7: Zerra PE, Parker ET, Baldwin WH, Healey JF, Patel SR, McCoy JW, Cox C, Stowell SR, Meeks SL. Engineering a Therapeutic Protein to Enhance the Study of Anti-Drug Immunity Biomedicines. 2022 Jul 18;10(7):1724._x000D_ 8: Zhu L, Ge F, Yang L, Li W, Wei S, Tao Y, Du G. Alginate Particles with Ovalbumin (OVA) Peptide Can Serve as a Carrier and Adjuvant for Immune Therapy in B16-OVA Cancer Model Med Sci Monit Basic Res. 2017 Apr 28;23:166-172._x000D_ 9: Pfeil J, Simonetti M, Lauer U, Volkmer R, von Thülen B, Durek P, Krähmer R, Leenders F, Hamann A, Hoffmann U. Tolerogenic Immunomodulation by PEGylated Antigenic Peptides Front Immunol. 2020 Oct 9;11:529035._x000D_ <a href="https://pubmed.ncbi.nlm.nih.gov/15080822">10: Barbey C, Donatelli-Dufour N, Batard P, Corradin G, Spertini F. Intranasal treatment with ovalbumin but not the major T cell epitope ovalbumin 323-339 generates interleukin-10 secreting T cells and results in the induction of allergen systemic tolerance Clin Exp Allergy. 2004 Apr;34(4):654-62. </a>_x000D_ _x000D_ <strong>Products Related to OVA Peptide (323-339) can be found at</strong> <a href="https://moleculardepot.com/product-category/Peptides/"> Peptides</a>